本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

CRISPR Therapeutics AG

52.53
+1.422.78%
盘前51.74-0.7897-1.50%09:08 EST
成交量:426.68万
成交额:2.23亿
市值:50.06亿
市盈率:-9.41
高:54.77
开:49.58
低:49.11
收:51.11
52周最高:78.48
52周最低:30.04
股本:9,530.02万
流通股本:9,053.30万
量比:1.63
换手率:4.71%
股息:- -
股息率:- -
每股收益(TTM):-5.5830
每股收益(LYR):-4.3416
净资产收益率:-25.33%
总资产收益率:-13.28%
市净率:2.61
市盈率(LYR):-12.10

数据加载中...

2024/08/05

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/06/03

重要事件披露

Form 8-K - Current report
2024/05/23

重要事件披露

Form 8-K - Current report
2024/05/08

季度报告

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2024/05/08

重要事件披露

Form 8-K - Current report
2024/04/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/04/10

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/03/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/03/15

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/21

年度报告

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
2024/02/21

重要事件披露

Form 8-K - Current report
2024/02/16

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/02/14

重要事件披露

Form 8-K - Current report
2024/02/13

重要事件披露

Form 8-K - Current report
2024/02/12

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/09

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/05

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/30

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/01/30

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/17

关联方拟减持公告

Form 144 - Report of proposed sale of securities